A review of the current status of siRNA nanomedicines in the treatment of cancer.
about
Clinical Translation of Nanomedicine.siRNA Delivery Strategies: A Comprehensive Review of Recent Developments.Nanometer-scale siRNA carriers incorporating peptidomimetic oligomers: physical characterization and biological activity.Targeted siRNA delivery reduces nitric oxide mediated cell death after spinal cord injuryLiposomal Formulations in Clinical Use: An Updated Review.Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.Systemic siRNA Nanoparticle-Based Drugs Combined with Radiofrequency Ablation for Cancer Therapy.Transdermal Delivery of Small Interfering RNA with Elastic Cationic Liposomes in Mice.pH-Sensitive carboxymethyl chitosan-modified cationic liposomes for sorafenib and siRNA co-delivery.RNA viruses and microRNAs: challenging discoveries for the 21st century.Cervical Cancer: Development of Targeted Therapies Beyond Molecular Pathogenesis.Systemic tumor-specific gene delivery.Poly(amidoamine) dendrimer complexes as a platform for gene delivery.Tumor-targeting multifunctional nanoparticles for siRNA delivery: recent advances in cancer therapy.Structure-property relationship for in vitro siRNA delivery performance of cationic 2-hydroxypropyl-β-cyclodextrin: PEG-PPG-PEG polyrotaxane vectorsSynthetic vectors for gene delivery: An overview of their evolution depending on routes of administration.Photocrosslinkable, biodegradable hydrogels with controlled cell adhesivity for prolonged siRNA delivery to hMSCs to enhance their osteogenic differentiation.Preliminary study of a novel transfection modality for in vivo siRNA delivery to vocal fold fibroblasts.Targeted siRNA Delivery Using a Lipo-Oligoaminoamide Nanocore with an Influenza Peptide and Transferrin Shell.Delivery strategies and potential targets for siRNA in major cancer typesEfficient in vitro gene therapy with PEG siRNA lipid nanocapsules for passive targeting strategy in melanoma.Biomaterials in siRNA Delivery: A Comprehensive Review.ScFv-decorated PEG-PLA-based nanoparticles for enhanced siRNA delivery to Her2⁺ breast cancer.Knockdown of ribosomal protein L39 by RNA interference inhibits the growth of human pancreatic cancer cells in vitro and in vivo.Protamine sulfate-calcium carbonate-plasmid DNA ternary nanoparticles for efficient gene delivery.Tumor-Associated Macrophages as Target for Antitumor Therapy.A New Approach for the Treatment of Arthritis in Mice with a Novel Conjugate of an Anti-C5aR1 Antibody and C5 Small Interfering RNA.Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect.Cationic fluorescent polymer core-shell nanoparticles for encapsulation, delivery, and non-invasively tracking the intracellular release of siRNA.Modified gold-based siRNA nanotherapeutics for targeted therapy of triple-negative breast cancer.Inulin-Ethylenediamine Coated SPIONs Magnetoplexes: A Promising Tool for Improving siRNA Delivery.Exosomal Non-Coding RNAs: Diagnostic, Prognostic and Therapeutic Applications in Cancer.Engineering nanoparticles to overcome barriers to immunotherapy.Stimuli responsive polymer-based strategies for polynucleotide deliverySiRNA silencing efficacy prediction based on a deep architecture
P2860
Q30355939-929B2EAB-540B-43DC-9147-E58E99254167Q33611947-B65ACE64-6CF3-4666-9DF3-CDF77F5C1B30Q33633338-4BED2DE5-6440-413B-B4DB-A2BAC1D23934Q33651175-935BD294-63E0-4B51-A9DF-BF34D46542F7Q33850427-40138FE9-FEAB-47AF-A630-623802BC51A5Q35587385-8B33B575-286C-4B6E-886F-63BF38ADBB8BQ35831738-379C1D9C-D88B-4A67-96D6-420689BA0A8AQ36112181-1AF1E44E-BA09-44AB-8BFC-47A275B8D619Q36137279-0072EC05-517E-4B91-A7AB-52BFDD245C93Q37346014-F87FAB38-A17C-4FC7-9363-1567F60419C4Q37579334-16DFB6EB-888B-4237-A316-B84BE34952CDQ38137609-7AA2800F-DB12-4448-968A-5E7B8734083DQ38156233-0E7980CF-D688-44CC-95D1-448DC806E09BQ38191832-B5EC8E7F-3882-4A3F-9A40-C1269F66FB6DQ38513174-00322AD4-8C77-49B8-9DF3-D42331CCE232Q38513773-EC57E839-E51E-4E3C-BF42-364FEAF6CA30Q38707859-F2C1D645-95F2-44E7-9DAC-0DC0E90ECBD9Q38725307-18104F01-5699-43B5-9736-F1077049212BQ38775787-CEEA5AC5-56B0-4E99-9371-0E74E6EE7C20Q38853191-B40F8051-5A81-44FA-B207-3B88FBFF012FQ38952654-7CF66226-60B9-4CF2-8C23-FCDBB1564DA4Q38971775-EF07161C-AA07-4A89-8DC7-4C2F93853E92Q38982783-7DD8A3A0-8246-435B-83AB-397A8E8385E6Q38998161-6BE617E9-6CAD-405C-9D1A-87582C21DB74Q39032945-90255C57-510A-4B9E-ABD3-6613813710C8Q39403895-92B7B1E5-1AAD-4962-9CF3-EC5AD931C585Q40734548-5E4E7965-CACC-49C2-BBED-7FF2BB4552ABQ45324119-39371BB2-7855-4DD9-BA19-7E47ED26871CQ48687614-375A034F-BBB9-45F1-B1EE-C5B33A4D3C37Q48711808-DE5684FB-8EB9-4F85-BE69-37E0A24AB9FBQ53464406-DE2D80ED-3691-44CD-AC88-F9240F43D24FQ54941005-92F056EA-287C-4CCB-B7C6-1616CCC62FF1Q54991276-5ECA3838-0712-4B0C-B815-E3CEAE740D8BQ57371723-4FE3EC0F-992C-40DA-8F0B-F3E47DCED581Q58700229-2D63ADC3-191F-4074-AB94-C23406E69D75
P2860
A review of the current status of siRNA nanomedicines in the treatment of cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
A review of the current status of siRNA nanomedicines in the treatment of cancer.
@en
type
label
A review of the current status of siRNA nanomedicines in the treatment of cancer.
@en
prefLabel
A review of the current status of siRNA nanomedicines in the treatment of cancer.
@en
P2093
P1433
P1476
A review of the current status of siRNA nanomedicines in the treatment of cancer.
@en
P2093
Catherine Passirani
Jean-Pierre Benoit
Pauline Resnier
Tristan Montier
Véronique Mathieu
P304
P356
10.1016/J.BIOMATERIALS.2013.04.060
P577
2013-05-30T00:00:00Z